Quick Answer
REGENEREX PHARMA, INC. reported R&D Expense of $662.5 thousand for fiscal year 2025.
REGENEREX PHARMA, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $662.5K | -72.4% |
| 2024 | $2.40M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $136.4K | — | +685.0% |
| December 31, 2024 | $17.4K | — | -99.3% |
| September 30, 2023 | $2.40M | — | +799900.0% |
| December 31, 2018 | $300.00 | — | — |
- REGENEREX PHARMA, INC. showed a decrease of -72.4% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, REGENEREX PHARMA, INC.’s r&d expense has declined by 72.4% (from $2.40 million to $662.5 thousand).
- The most recent figure is from REGENEREX PHARMA, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: